It will become the second drug plant in Rwanda after Moroccan based Cooper Pharma.
The plant will manufacture generic pharmaceutical formulations in all major therapeutics in a variety of dosage forms including tablets, capsules, powder for suspension (PFS), liquid syrups and oral rehydration therapy.
This project to be built in two phases involves the establishment of a state-of-the-art GMP-compliant pharmaceutical manufacturing plant with an annual capacity of 800 million pcs of tablets, 200 million capsules, 8 million bottles and 5 million ORT sachets at optimum capacity utilization.
Herbeton Madari, the Managing Director of Apex Biotech Pharmaceutical-Rwanda said that the firm will advance science for life in the country and provide “high-quality and affordable” medicine that compliments Rwanda’s life expectancy mark and boosting economic growth.
“Our products and technologies will be used to prevent and treat a wide range of medical conditions, including malaria, HIV/AIDS, TB, Hepatitis as well as non-communicable diseases like heart diseases, diabetes, malnutrition, women’s and children’s health and chronic pain conditions,” said Namzul Ahasan Sarker, the managing director of Bangladesh-based Health City.
Dr. Diane Gashumba said the Minister of Health, this will go a long way in reducing foreign exchange Rwanda invests in importing medicines, create jobs as well as improve the quality of healthcare in Rwanda.
Apex Biotech Ltd is co-owned by Rwandans and Bangladeshi investors. The drug plant is expected to open within the next nine months.